-transparent.png){kind=logo}
Retinoic acid and hydrocortisone (HC) have been shown to regulate the drug sensitivity of the blast cells of acute myeloblastic leukemia (AML). We asked if the proto-oncogene bcl-2 played a role in this regulation. As target cells we used the continuous lines, OCI/AML-1, OCI/AML-2 or OCI/AML-5; expression of bcl-2 can be detected by Northern analysis of RNA from OCI/AML-2 or OCI/AML-5 cells; bcl-2 expression can be found in OCI/AML-1 cells only by using RT-PCR. Exposure of OCI/AML-2 or OCI/AML-5 cells to retinoic acid (all-trans retinoic acid, ATRA) led to a down-regulation of bcl-2 expression that was first seen after 2 h of exposure and was complete after a day. The down-regulation could be prevented by exposing the cells to ara-C either before or after ATRA; decrease in bcl-2 protein was moderate and only obvious after 36 h of ATRA treatment. Nuclear run-on experiments provided evidence that bcl-2 down-regulation was occurring at transcriptional and post-translational levels. Since bcl-2 is considered to have anti-oxidant activity, we tested the sensitivity of the three cell lines to H2O2; we found that OCI/AML-1, the line with very low bcl-2 expression, was a 100-fold more H2O2-sensitive than OCI/AML-2 or OCI/AML-5, where bcl-2 expression can be detected readily. We then asked if H2O2 sensitivity could be regulated. We found that exposure of cells to HC before H2O2 was protective while ATRA after peroxide treatment increased killing; this is the same pattern of regulation observed when AML blasts are exposed to HC before, or ATRA after ara-C. Finally, we asked whether N-acetylcysteine (NAC), a known radical scavenger would protect cells against ara-C killing. Significant protection was observed when NAC was given before drug, but not if given after drug. NAC protection against ara-C killing was seen for OCI/AML-1 and 2 cells, but not for OCI/AML-5 cells. We interpret the results as follows: ara-C kills cells in two ways: first, directly, by incorporation into DNA and chain termination; second, indirectly, by inducing the production of toxic radicals. Bcl-2 reduces the oxidant activity of such radicals, and is protective. ATRA regulates ara-C toxicity by its action on bcl-2. Left unexplained are the action of HC, which does not affect bcl-2 expression and the mechanism by which ara-C prevents down-regulation of bcl-2 by ATRA.
Z B Hu, and
G S Yang, and
M Li, and
N Miyamoto, and
M D Minden, and
E A McCulloch
March 1986,
Blood,
Z B Hu, and
G S Yang, and
M Li, and
N Miyamoto, and
M D Minden, and
E A McCulloch
November 1989,
Leukemia,
Z B Hu, and
G S Yang, and
M Li, and
N Miyamoto, and
M D Minden, and
E A McCulloch
July 1991,
Journal of cellular physiology,
Z B Hu, and
G S Yang, and
M Li, and
N Miyamoto, and
M D Minden, and
E A McCulloch
October 1972,
Ugeskrift for laeger,
Z B Hu, and
G S Yang, and
M Li, and
N Miyamoto, and
M D Minden, and
E A McCulloch
January 1973,
Acta haematologica Polonica,
Z B Hu, and
G S Yang, and
M Li, and
N Miyamoto, and
M D Minden, and
E A McCulloch
September 1977,
Cancer,
Z B Hu, and
G S Yang, and
M Li, and
N Miyamoto, and
M D Minden, and
E A McCulloch
September 1984,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
Z B Hu, and
G S Yang, and
M Li, and
N Miyamoto, and
M D Minden, and
E A McCulloch
March 1971,
Minerva medica,
Z B Hu, and
G S Yang, and
M Li, and
N Miyamoto, and
M D Minden, and
E A McCulloch
June 1971,
Lancet (London, England),
Z B Hu, and
G S Yang, and
M Li, and
N Miyamoto, and
M D Minden, and
E A McCulloch
January 1992,
Hematologic pathology,
